{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:48:14Z","timestamp":1649083694363},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00280-008-0775-x","type":"journal-article","created":{"date-parts":[[2008,5,26]],"date-time":"2008-05-26T12:19:31Z","timestamp":1211804371000},"page":"745-748","source":"Crossref","is-referenced-by-count":1,"title":["Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report"],"prefix":"10.1007","volume":"63","author":[{"given":"Celalettin","family":"Camci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Sevinc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilmaz","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Emin","family":"Kalender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman","family":"Buyukberber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,27]]},"reference":[{"key":"775_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43\u201366","journal-title":"CA Cancer J Clin"},{"key":"775_CR2","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1001\/jama.1983.03340220040030","volume":"250","author":"RC Young","year":"1983","unstructured":"Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP (1983) Staging laparotomy in early ovarian cancer. JAMA 250:3072\u20133076","journal-title":"JAMA"},{"key":"775_CR3","doi-asserted-by":"crossref","unstructured":"Samaritani R, Corrado G, Vizza E, Sbiroli C (2007) Cyclophosphamide \u201cmetronomic\u201dchemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer, doi: 10.1186\/1471-2407-7-65","DOI":"10.1186\/1471-2407-7-65"},{"key":"775_CR4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1200\/JCO.2001.19.5.1266","volume":"19","author":"C Doyle","year":"2001","unstructured":"Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266\u20131274","journal-title":"J Clin Oncol"},{"key":"775_CR5","first-page":"179","volume":"21","author":"A Latorre","year":"2002","unstructured":"Latorre A, De Lena M, Catino A, Crucitta E, Sambiasi D, Guida M, Misino A, Lorusso V (2002) Epithelial ovarian cancer: second andthird line chemotherapy. Int J Oncol 21:179\u2013186","journal-title":"Int J Oncol"},{"key":"775_CR6","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1998.16.10.3461","volume":"16","author":"A Sulkes","year":"1998","unstructured":"Sulkes A, Benner SE, Canetta RM (1998) Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 16:3461\u20133475","journal-title":"J Clin Oncol"},{"key":"775_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00003495-199958003-00011","volume":"58","author":"PM Hoff","year":"1999","unstructured":"Hoff PM, Lassere Y, Pazdur R (1999) Tegafur\/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil (Review; 43 refs). Drugs 58:77\u201383","journal-title":"Drugs"},{"key":"775_CR8","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","volume":"322","author":"RC Young","year":"1990","unstructured":"Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021\u20131027","journal-title":"N Engl J Med"},{"key":"775_CR9","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","volume":"22","author":"M Markman","year":"2004","unstructured":"Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120\u20133125","journal-title":"J Clin Oncol"},{"key":"775_CR10","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1200\/JCO.2005.02.2582","volume":"23","author":"A Santillan","year":"2005","unstructured":"Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, Bristow RE (2005) Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23:9338\u20139343","journal-title":"J Clin Oncol"},{"key":"775_CR11","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2006.09.4540","volume":"25","author":"PY Liu","year":"2007","unstructured":"Liu PY, Alberts DS, Monk BJ, Brady M, Moon J, Markman M (2007) An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 25:3615\u20133620","journal-title":"J Clin Oncol"},{"key":"775_CR12","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","volume":"92","author":"I Vergote","year":"2000","unstructured":"Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB (2000) Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92:1534","journal-title":"J Natl Cancer Inst"},{"key":"775_CR13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S1470-2045(07)70357-1","volume":"8","author":"A Sevinc","year":"2007","unstructured":"Sevinc A, Adli M, Kalender ME, Camci C (2007) Benign causes of increased serum CA-125 concentration. Lancet Oncol 8:1054\u20131055","journal-title":"Lancet Oncol"},{"key":"775_CR14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000074425","volume":"24","author":"HM Turk","year":"2003","unstructured":"Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24:172\u2013175","journal-title":"Tumour Biol"},{"key":"775_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000071198","volume":"65","author":"A Sevinc","year":"2003","unstructured":"Sevinc A, Camci C, Turk HM, Buyukberber S (2003) How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 65:1\u20136","journal-title":"Oncology"},{"key":"775_CR16","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/archinte.161.20.2507-a","volume":"161","author":"A Sevinc","year":"2001","unstructured":"Sevinc A, Sari R, Buyukberber S (2001) Cancer antigen 125: tumor or serosal marker in case of ascites? Arch Intern Med 161:2507\u20132508","journal-title":"Arch Intern Med"},{"key":"775_CR17","first-page":"1201","volume":"20","author":"A Sevinc","year":"2000","unstructured":"Sevinc A, Buyukberber S, Sari R, Turk HM, Ates M (2000) Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res 20:1201\u20131203","journal-title":"Anticancer Res"},{"key":"775_CR18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/gyno.2000.5776","volume":"77","author":"A Sevinc","year":"2000","unstructured":"Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M (2000) Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 77:254\u2013257","journal-title":"Gynecol Oncol"},{"key":"775_CR19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/gyno.1999.5670","volume":"76","author":"A Sevinc","year":"2000","unstructured":"Sevinc A, Buyukberber S, Sari R (2000) Elevated serum CA-125 levels: hepatitis or ascites? Gynecol Oncol 76:141\u2013142","journal-title":"Gynecol Oncol"},{"key":"775_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00000421-199502000-00004","volume":"18","author":"KY Look","year":"1995","unstructured":"Look KY, Muss HB, Blessing JA, Morris M (1995) A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 18:19\u201322","journal-title":"Am J Clin Oncol"},{"key":"775_CR21","first-page":"2219","volume":"19","author":"N Ohwada","year":"1992","unstructured":"Ohwada N, Nagayama M, Kosuge T, Tsukagoshi T, Ibuki Y, Igarashi M, Yazaki K, Ito T, Nogami Y, Kimura H (1992) Maintenance chemotherapy using UFT and FT for gynecological malignant tumors (in Japanese). The Gunma Prefectural Society for Study of Chemotherapy for Gynecological Cancer. Gan To Kagaku Ryoho 19:2219\u20132226","journal-title":"Gan To Kagaku Ryoho"},{"key":"775_CR22","first-page":"407","volume":"17","author":"JT Chen","year":"1990","unstructured":"Chen JT, Nakayama K, Shimizu Y, Yokosuka K, Teshima H, Hirai Y, Hamada T, Fujimoto I, Yamauchi K, Hasumi K (1990) Evaluation of UFT administration in patients with ovarian cancer who had no evidence of disease after the initial therapy (in Japanese). Gan To Kagaku Ryoho 17:407\u2013412","journal-title":"Gan To Kagaku Ryoho"},{"key":"775_CR23","first-page":"1229","volume":"2","author":"K Tanaka","year":"1994","unstructured":"Tanaka K, Kodama S, Nakamura M, Takahashi T, Honma S, Maruhashi T, Tokunaga A, Takeuchi Y, Sudou N, Adachi S (1994) Clinical results of UFT against ovarian carcinoma (in Japanese). Gan To Kagaku Ryoho 2:1229\u20131233","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0775-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0775-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:53Z","timestamp":1559038013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0775-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,27]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0775-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,27]]}}}